Hybrid-designed inhibitors of p38 MAP kinase utilizing N-arylpyridazinones

J Med Chem. 2003 Jan 30;46(3):349-52. doi: 10.1021/jm025585h.

Abstract

Imidazo[1,2-a]pyridyl N-arylpyridazinones were hybridized from the classic pyridinylimidazoles and the more recent dual hydrogen bond acceptors, resulting in a new structural class of selective p38 MAP kinase inhibitors.

MeSH terms

  • Animals
  • Enzyme Inhibitors / chemical synthesis*
  • Enzyme Inhibitors / chemistry
  • Enzyme Inhibitors / pharmacology
  • Mice
  • Mitogen-Activated Protein Kinases / antagonists & inhibitors*
  • Mitogen-Activated Protein Kinases / chemistry
  • Models, Molecular
  • Pyridazines / chemical synthesis*
  • Pyridazines / chemistry
  • Pyridazines / pharmacology
  • Structure-Activity Relationship
  • p38 Mitogen-Activated Protein Kinases

Substances

  • Enzyme Inhibitors
  • Pyridazines
  • Mitogen-Activated Protein Kinases
  • p38 Mitogen-Activated Protein Kinases